id: NEW:criminal_justice_officer_support_for_moud_to_sud_medication_treatment_rate_oud
name: Officer and Judge Support for Extended-Release Naltrexone â†’ OUD Medication Treatment Rate
from_node:
  node_id: NEW:criminal_justice_officer_support_for_moud
  node_name: Officer and Judge Support for Extended-Release Naltrexone
to_node:
  node_id: sud_medication_treatment_rate_oud
  node_name: OUD Medication Treatment Rate
direction: positive
category: social_environment
mechanism_pathway:
- 'Step 1: Criminal justice officers and judges express supportive attitudes toward extended-release naltrexone'
- 'Step 2: Supportive attitudes reduce barriers and create enabling environment for treatment initiation'
- 'Step 3: Justice-involved individuals feel encouraged to pursue MOUD treatment'
- 'Step 4: Increased initiation rates for extended-release naltrexone among supervised population'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Marisa D Booty et al. 2023. "Barriers and facilitators to the use of medication for
    opioid use disorder within the criminal justice system: Perspectives from clinicians.." https://doi.org/10.1016/j.josat.2023.209051'
  supporting_citations:
  - Additional citations require full-text access - qualitative interview study with 25 social service
    clinicians
  - Study references attitudinal facilitators of MOUD initiation (citation in full text)
  - Study references promoting recovery and remission among justice-involved individuals (citation in
    full text)
  doi: 10.1016/j.josat.2023.209051
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Positive attitudes from criminal justice officers and judges toward extended-release naltrexone
  facilitate MOUD treatment initiation among justice-involved individuals with OUD.
quantitative_effects:
  sample_size: 25
moderators:
- name: medication_type
  direction: strengthens
  strength: moderate
  description: Support specifically noted for extended-release naltrexone; attitudes toward other MOUD
    types may differ
structural_competency:
  equity_implications: While attitudinal support from authority figures facilitates treatment access,
    the selective support for antagonist therapy (naltrexone) over agonist therapies (buprenorphine, methadone)
    reveals persistent structural bias in the criminal justice system's approach to addiction treatment.
    True structural competency requires evidence-based support for all MOUD options.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.774107'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
